Vabon

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vabon

Property Description
Active ingredient Vonoprazan (a synthetic compound)
Form Oral tablet
Pharmacological class Potassium-Competitive Acid Blocker (PCAB)
General purpose Potent reduction of stomach acid
Origin / Status Synthetic / Prescription-only (Rx)

What Type of Medicine is Vabon (Vonoprazan)?

Vabon is a prescription drug whose active ingredient is vonoprazan, classified as a first-in-class Potassium-Competitive Acid Blocker (PCAB).

Vonoprazan is a highly effective gastric acid secretion inhibitor that powerfully and rapidly reduces the amount of acid produced in the stomach. The active substance is a synthetic organic compound and a reversible inhibitor of the gastric proton pump. This means the medicine works by directly turning off the mechanism that creates stomach acid. Vabon's general purpose is to achieve strong, sustained acid suppression, which is recognized for providing significant relief in conditions like erosive esophagitis.


What is Vabon Made Of and What Form Does It Come In?

Vabon is a single-ingredient formulation containing only the active ingredient, vonoprazan, and it is supplied as an oral tablet.

This drug is available only by prescription (Rx status) and is known in the U.S. under the brand name Voquezna. Its primary use targets disorders related to acid secretion, such as peptic ulcer and reflux esophagitis. This drug is specifically designed to control the amount of acid in your stomach. The solid tablet form allows for a convenient and stable way to administer the precise dose of the active ingredient into the digestive system.


How Does Vabon Differ from Other Acid Blockers?

Vabon (a PCAB) is fundamentally different from older medications like Proton Pump Inhibitors (PPIs) because it blocks the acid-producing pump reversibly and does not require acid activation.

This mechanism offers advantages over traditional PPIs, including stability in acidic conditions, which contributes to its potency and rapid effect. The pharmacological profile of vonoprazan allows it to achieve acid suppression more quickly and consistently than standard therapies. This characteristic is the source of its key general benefit: providing rapid and powerful acid suppression for patients needing swift relief.

Regulatory References

  1. IUPHAR: Vonoprazan (Ligand ID 11549)
  2. Vonoprazan as a P-CAB (IUPHAR)

What side effects are possible with Vabon?

Possible Side Effects and Safety Information

The official safety profile of vonoprazan is classified by regulatory agencies based on the frequency and system-organ class of reported adverse reactions. This classification includes effects observed during clinical trials and post-marketing surveillance, establishing the medicine's documented risk profile.

Adverse Reaction Scope

Adverse reactions are formally grouped into categories such as Gastrointestinal disorders, Nervous System disorders, Infections and Infestations, and changes observed in Laboratory Investigations.

Classification Examples of Documented Reactions
Common (May affect up to 1 in 10 people) Diarrhea, Nausea, Abdominal pain, Headache, Gastritis, Dyspepsia, Urinary Tract Infection, Nasopharyngitis.
Uncommon (May affect up to 1 in 100 people) Rash, Hypersensitivity reactions, Leukopenia, and increases in specific liver enzymes (e.g., ALT, GGT).

Serious Adverse Reactions and Safety Constraints

The label documents rare but medically significant serious adverse reactions, including Severe Cutaneous Adverse Reactions (such as Stevens-Johnson syndrome) and generalized Hypersensitivity Reactions (including anaphylactic shock). Acute Tubulointerstitial Nephritis and Clostridioides difficile-Associated Diarrhea (CDAD) have also been reported with acid-reducing agents.

Safety-Related Limitations: Vabon is contraindicated in individuals with a known hypersensitivity to the drug. The drug is generally not recommended in specific cases of severe hepatic or renal impairment, and its use in combination with certain antiviral medications is restricted.

Duration-Related Safety: Long-term acid suppression therapy is associated with documented risks, including Fundic Gland Polyps and Bone Fracture.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Vabon (Vonoprazan)


Overdose Scope

Entity Official Regulatory Statement
Documented overdose presentations No specific clinical experience of overdose with vonoprazan is formally documented in regulatory sources.
Emergency-response statements Treatment for overdose should be symptomatic and supportive.
When immediate medical help is required In the event of an overdose, contact emergency medical services or a Poison Control Center immediately; treatment should be symptomatic and supportive.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Antidote availability No specific antidote is known for vonoprazan.
Overdose-context constraints Vonoprazan is not removed from the circulation by hemodialysis.

Resulting Overdose Structure

Official overdose statements:

  • The official prescribing information states that there is no specific clinical experience of overdose with vonoprazan in human subjects.
  • No specific antidote is known for vonoprazan.
  • Management in the event of an overdose must be symptomatic and supportive.

Connection to the overall overdose profile (2–4 sentences):

Regulatory documents define the overdose profile for Vabon primarily through the absence of documented human overdose cases. The mandated action for suspected overdose is to seek urgent medical attention, where the officially described course of action is to provide symptomatic and supportive treatment. This approach is informed by the formal statement that the drug cannot be removed effectively via hemodialysis by medical personnel.

Therapeutic Uses of Vabon

Quick Facts: Vabon

  • Therapeutic Domain: Treatment of certain gastrointestinal conditions.
  • Key Indication: Supports the healing and management of erosive esophagitis.
  • Secondary Use: Used in specific combination therapies for Helicobacter pylori (H. pylori) infection.

What Vabon Treats: Main Uses and Benefits

Vabon is a prescription medication utilized in the management of specific conditions affecting the esophagus and stomach. Its primary approved role is to support the healing of erosive esophagitis in adult patients. Erosive esophagitis is a condition characterized by damage to the lining of the esophagus, often associated with frequent or severe heartburn.

The medication is also indicated for the maintenance of healed erosive esophagitis, which helps to manage the condition over time and reduce the likelihood of recurrence. By addressing the underlying issues that contribute to the damage, Vabon helps patients maintain their therapeutic gains.

Additionally, Vabon is included as a component in certain combination regimens for the treatment of H. pylori infection. This type of infection is a common cause of peptic ulcers and chronic gastritis. Its use in this context is intended to manage the bacterial load when administered with other necessary antibiotics.

Eligibility and Restrictions for Use

Who Can and Cannot Use Vabon?

Eligibility for Vabon (vonoprazan) is strictly defined by regulatory authorities based on age, existing health conditions, and reproductive status. The medicine is primarily approved for use in adult patients (18 years and older) for all labeled indications, including healing and maintenance of erosive esophagitis.

Contraindicated Populations

Use of Vabon is contraindicated (absolutely prohibited) for two main groups:

  • Patients with a known hypersensitivity to vonoprazan or any component of the formulation.
  • Patients concurrently receiving rilpivirine-containing products.

Restricted and Non-Established Use

Population Group Eligibility Status Restriction Basis
Pediatric Patients (under 18) Not Established Safety and effectiveness have not been established by regulators.
Pregnant Women Restricted No adequate and well-controlled human studies exist to inform risk.
Lactating Women Not Recommended Advised against due to potential for serious adverse effects shown in animal studies.
Severe Hepatic/Renal Impairment Restricted/Not Recommended Use is limited or not recommended for specific indications, such as H. pylori treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information describes a number of pharmacokinetic and pharmacodynamic interaction patterns for vonoprazan. A combination with rilpivirine-containing products is formally contraindicated, as the drug's effect on gastric pH may significantly decrease rilpivirine’s plasma concentration and efficacy. The potent acid suppression may similarly reduce the absorption and exposure of other pH-dependent medicines, such as atazanavir, nelfinavir, and certain oral tyrosine kinase inhibitors.

Vonoprazan is primarily metabolized by the CYP3A4 enzyme, which results in two documented interaction classes. Co-administration with strong or moderate CYP3A4 inducers (e.g., rifampin, phenytoin) decreases vonoprazan exposure. Conversely, strong or moderate CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) increase vonoprazan exposure.

Regarding diagnostics, vonoprazan treatment must be temporarily discontinued for at least four weeks before assessing serum Chromogranin A ( CgA) levels due to the risk of false-positive results. Additionally, regulatory documents note that vonoprazan exposure is increased in patients with severe hepatic or renal impairment compared to healthy subjects.

Mechanism of Action

How Vabon Works: Mechanism of Action

Vabon operates through a synergistic dual-inhibitor mechanism targeting essential bacterial processes. The mechanism involves two components: meropenem and vaborbactam.

The vaborbactam component acts as a non-competitive inhibitor of bacterial serine beta-lactamase enzymes, such as K. pneumoniae carbapenemase (KPC). By forming a stable, covalent bond with the enzyme's active site, vaborbactam prevents the hydrolytic degradation of meropenem. This process modulates a key bacterial defense pathway, allowing the primary drug to remain intact.

The protected meropenem component then functions as a covalent inhibitor of bacterial penicillin-binding proteins (PBPs), which are transpeptidases essential for cell wall synthesis. Inhibition of PBPs blocks the final step in the peptidoglycan cross-linking pathway. This disruption of structural integrity activates bacterial autolytic enzymes, initiating the final cascade of osmotic lysis. The resulting physiological consequence is cellular lysis, leading to a decrease in the number of susceptible bacteria.

Dosage and Administration Information

How Vabon Is Used: Official Administration Guidelines

Vabon, whose active ingredient is vonoprazan, is designed to be administered orally as a 10 mg or 20 mg tablet. The administration procedure is standardized: the tablet must be swallowed whole and must not be crushed or chewed before swallowing. Vabon can be taken with or without food, providing flexibility in its daily timing.


Official Dosing Regimens and Course Duration

The required dose and frequency of Vabon are strictly dependent on the specific condition being managed, and all regimens are defined by fixed, time-limited courses:

  • Healing Erosive Esophagitis (EE): The standard dose is 20 mg taken once daily for a duration of eight weeks.
  • Maintenance of Healed EE: Following the healing phase, the dose is typically 10 mg taken once daily for a course lasting up to six months.
  • H. pylori Eradication: Vabon is administered at 20 mg twice daily for 14 days as the proton-blocking component within a defined combination therapy.

Procedural Adjustments and Handling Missed Doses

Dose modifications are established for certain populations. For patients with severe renal impairment or moderate to severe hepatic impairment, the dose for healing EE is reduced to 10 mg once daily. Use in H. pylori eradication is not recommended for these patient groups.

Instructions for a missed dose vary by indication. For EE (healing or maintenance), the dose should be taken as soon as possible if it is within 12 hours of the scheduled time; otherwise, it is skipped. For the H. pylori eradication regimen, the window for taking a missed dose is shorter, at within 4 hours of the scheduled time. These explicit instructions define the necessary procedural constraints for the medicine's proper use.

Recent Clinical Evidence

Research evidence / Overview of studies for Vabon

This overview summarizes the available research regarding Vabon (vonoprazan) for its approved uses. It focuses on the type of research conducted and the outcomes measured, without making claims about effectiveness or providing medical advice. Findings described reflect group patterns observed in studies and do not determine whether an individual will respond similarly.


Research Evidence for the Healing of Erosive Esophagitis

This section summarizes findings from short-term Randomized Controlled Trials (RCTs) and meta-analyses that examined research exploring Vabon in the context of the acute healing of damaged esophageal lining in adult patients. Researchers explored short-term changes in the esophagus by conducting controlled studies, typically lasting up to eight weeks. These trials were interested in two outcomes: the endoscopic healing rate (checking the esophagus for absence of damage) and the level of heartburn relief reported by participants. Studies reported measurements of esophageal healing confirmed by endoscopy.

However, the existing evidence primarily provides insights into the short-term healing phase. The available research provides limited data on outcomes reported beyond the initial 8-week acute healing phase.


Research Evidence for Maintaining Healed Esophagitis

This part of the overview focuses on evidence from medium-term controlled trials and long-term extensions that studied the durability of healing and the prevention of relapse. These studies monitored the recurrence of erosive damage and the frequency of patient-reported discomfort (heartburn) over periods primarily lasting up to six months. Findings describe patterns observed in the studies, where research explored how frequently patients maintained the healed state. Dedicated, large-scale studies exploring long-term outcomes have limited data available for sustained use over multiple years.


Research Evidence for H. pylori Eradication

This summary focuses on the RCTs that evaluated Vabon as a component in multi-drug antibiotic regimens (dual or triple therapy) used to clear H. pylori bacterial infection. The main outcome monitored was the eradication rate of the bacterium, confirmed by laboratory tests several weeks after treatment finished. Research explored adult populations, including analysis of outcomes in strains that were resistant to common antibiotics. Data show patterns related to bacterial clearance across various Vabon-based antibiotic combinations.

Key Studies & References

  1. Vonoprazan for healing and maintenance of healing of erosive esophagitis: a randomized controlled trial (PHOENIX Study)
  2. NICE Guidelines on Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

Frequently Asked Questions (FAQ)

Common questions about Vabon (FAQ)


Q: Can Vabon be used by people with mild kidney issues?

A: Official documents primarily address use in patients with severe renal impairment, where a lower dose may be specified for some conditions. Use in people with mild or moderate kidney issues is not generally noted to require a dose adjustment for healing EE in official prescribing information.


Q: What if I start taking a new over-the-counter medicine while using Vabon?

A: Official information advises discussing all new medicines, including over-the-counter products and herbal supplements, with a healthcare provider before starting them. This consultation is necessary to evaluate the potential for drug interactions, as Vabon can interact with many other substances.


Q: Can I take Vabon if I am already taking an anti-depressant?

A: Vabon is processed by the liver using an enzyme system called extbfCYP3A4. Because some anti-depressant medications can affect this system, co-administration with this class of drugs requires review by a healthcare provider. This ensures any potential change in how Vabon is processed is managed.


Q: Are there any long-term studies on the use of Vabon?

A: Studies have provided clinical data through the 6-month maintenance phase of treatment. Regulatory documents state that there is limited data available on the use of Vabon for sustained periods beyond multiple years. The long-term risks associated with acid suppression therapy, such as bone fracture, are documented.


Q: How long does it typically take to notice the effects of Vabon?

A: Studies indicate that Vabon has a fast onset of action as it is a P-CAB (Potassium-Competitive Acid Blocker). Initial research suggests that potent acid suppression can be achieved quickly, sometimes within extbf30 minutes of taking the medicine.


Q: Does Vabon cause weight gain, according to studies?

A: Weight gain is not listed as a common side effect in the official product information. However, extbfunusual weight gain has been noted in rare reports and may be a reason to consult a healthcare provider. extbfWeight loss is also a less common documented side effect.


Q: Why do some people say Vabon makes them feel tired?

A: Official safety information includes extbffatigue and extbfunusual tiredness or weakness as documented side effects. These effects are generally considered less common but are reported in the clinical trial data.


Q: Is Vabon available as a generic medicine?

A: According to regulatory status information, Vabon is a brand-name medication (also known as Voquezna). Studies and official documents indicate that a generic form of the drug is not currently available on the market.


Q: Is there any research evidence on Vabon in older adults (seniors)?

A: Regulatory documents state that people over the age of 65 may be at a greater risk for experiencing certain side effects. Official documents indicate that older adults may require careful assessment by a healthcare provider.


Q: Do I need special monitoring when starting Vabon?

A: Regulatory documents mention that laboratory values, such as magnesium and calcium levels, may require assessment, especially in at-risk patient populations. Additionally, Vabon can interfere with extbfChromogranin A (CgA) testing.


Q: Can Vabon affect my ability to drive or operate machinery?

A: Official safety information notes documented side effects such as dizziness and extbfdrowsiness. Due to the possibility of these effects, regulatory information advises caution when driving or operating machinery until you know how the medicine affects you.


Q: How long after stopping Vabon does it stay in my system?

A: The elimination half-life of the active ingredient, vonoprazan, is noted in research and regulatory documents to be approximately 10 to 12 hours. This figure represents the time it takes for half of the drug to be eliminated from the body, though the average oral half-life is sometimes noted as longer.


Q: Is Vabon known to interact with herbal supplements?

A: Yes, regulatory documents note possible interactions with certain herbal supplements. This includes extbfSt. John's wort, which can interfere with the CYP3A4 enzyme that processes Vabon. Official information advises consulting a healthcare provider about all herbal products.


Q: Are there any known issues with Vabon and alcohol consumption?

A: Official information does not describe any specific pharmacokinetic interaction (how the body processes the drugs) with alcohol. However, official information notes that alcohol consumption may contribute to an increase in certain documented side effects, such as headache, nausea, and dizziness. Alcohol can also sometimes worsen the underlying medical condition Vabon is prescribed to manage.


Q: Can I take Vabon if I have a history of heart issues?

A: The single-ingredient drug is not formally contraindicated for heart issues. However, official information for one of the H. pylori combination products includes a warning for potential QT prolongation (a change in heart rhythm) due to one of the partner antibiotics. This is a consideration for patients with pre-existing heart conditions.


Q: Does Vabon have a warning about affecting blood pressure?

A: Official product information indicates that high blood pressure (Hypertension) is listed as a common adverse reaction occurring in clinical trials.


Q: What is the typical time frame for Vabon to reach its full expected effect?

A: The medicine achieves extbfrapid acid suppression shortly after the first dose. However, the full expected clinical benefit, such as the complete healing of the esophagus, is linked to the duration of the entire extbffixed-course treatment, which may last up to extbf8 weeks depending on the condition.


Q: Is Vabon addictive or habit-forming?

A: Regulatory bodies, such as the DEA, have not classified Vabon as a controlled substance. This means the drug does not have an abuse or dependence potential that necessitates special scheduling.


Q: Where can I find the official FDA documents about Vabon?

A: The FDA-approved labeling, or the package insert, for Vabon is made publicly available. You can find this authoritative information on governmental websites such as the extbfDailyMed or the extbfNIH MedlinePlus website.


Q: Are the side effects of Vabon temporary or do they usually last?

A: Official regulatory documents describing adverse events state that side effects observed in clinical studies were generally extbfmild or moderate in severity and transient in nature. This suggests the effects typically subsided, but the duration of any specific side effect cannot be guaranteed.


Q: Is Vabon a controlled substance?

A: According to regulatory assessments, Vabon is not classified as a controlled substance by the DEA.


Q: Is it normal to feel a change in appetite when starting Vabon?

A: Yes, the official product information lists a extbfloss of appetite or extbfdecreased appetite as documented side effects. These effects have been reported in clinical studies.


Q: Does Vabon interact with common vitamins like Vitamin D or B12?

A: Official safety information notes a risk of extbfVitamin B12 deficiency with the long-term use of acid-reducing agents. For this reason, it is recommended that all vitamin and mineral products are reviewed by a healthcare provider.


Q: What is the purpose of the black box warning on Vabon, if applicable?

A: Official labeling for the single-ingredient drug Vabon does not carry a Black Box Warning ( BBW). However, the official package insert for the extbfcombination product used for extitH. pylori eradication includes a BBW related to the extbfantibiotic component of that therapy.


Q: Can Vabon cause changes in mood or anxiety levels?

A: Official safety information includes extbfanxiety, depression, and extbfmood or mental changes as documented side effects. These effects are considered less common but were reported in clinical studies.


Q: What does 'contraindication' mean in the context of Vabon?

A: A extbfcontraindication is a specific factor or condition that formally prohibits the use of a medicine. In the context of Vabon, official sources list conditions like known extbfhypersensitivity to the drug as contraindications because the risk of harm would outweigh the potential benefit.


Q: Can Vabon be taken by people with diabetes?

A: Official documents do not list extbfdiabetes as a formal contraindication for using Vabon. However, extbfDiabetes mellitus has been noted in some reports as a less common side effect.

How should Vabon be stored and disposed of?

How to Store and Dispose of Vabon?

Vabon must be stored and handled according to specific regulatory requirements to ensure its stability and potency. The medicine generally requires refrigeration (e.g., 2 C to 8 C) and must not be frozen. It is essential to keep Vabon in its original outer carton to protect the product from light and/or moisture.

Regulatory documents specify a limited in-use stability period after opening, dilution, or reconstitution; typically, the product must be used immediately or within a defined short period (e.g., 8 hours).

To prevent accidental exposure, Vabon must be kept out of sight and reach of children. Unused or expired Vabon should be disposed of by a drug take-back program. If one is unavailable, follow specific official guidance, which may include mixing the medicine with an undesirable substance before disposal in household trash, or flushing if explicitly authorized by regulatory bodies due to the high risk of accidental ingestion. Disposal must comply with local requirements.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vabon found in:

A-Z Index: